Birds's Eye
Technicals
MovingAverage
Candlestick
PivotPoint
Fin Statements
Beta&Vols
Tech Charts
Future/OptionFundamental Analysis of Zydus Lifesciences Ltd. - Growth / Value Index
ZYDUSLIFE - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.830
Tremendous increasing in Book Value last 3 year
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Price to Earning | 21.44 | 19.71 | -25.37 % | ||
| Price to Book | 3.98 | 3.72 | -27.56 % | 1.80 | |
| Price to Sales | 4.15 | 3.84 | -26.40 % | ||
| Enterprise Value to EBITDA Multiple | 12.88 | -28.81 % |
ZYDUSLIFE - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Good Score of 65.62
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 20.53%
All key Trailing Twelve Months Margin growing by 15 %
Annual Net Profit in last 3 years is trending up
Company's Net Profit is increasing for last 5 Quarters
EBITDA is continuously increasing for last 3 Years
Steady Growth in EPS for last four quarters
Good Return On Capital Employed of 17.01
Good Net Margin of 19.37% is achieved by the company
Very Low Dividend Yield of 0 %
Low Earning Yield of 4.67 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|---|
| Return On Equity | 20.53 | 18.89 | -2.93 % | 5.56 | |
| Return On Asset | 13.72 | 12.16 | -7.71 % | 3.94 | |
| Net Profit Margin | 19.37 | 19.47 | -1.38 % | 22.31 | |
| Operating Profit Margin | 62.59 | 25.72 | 10.75 % | 30.90 | |
| EBITDA Margin | 30.24 | 30.58 | 5.74 % | 33.83 |
Highlights
| Market Cap | 980524 M |
| Enterprise Value | 1004.07 B |
| Price/Book TTM | 3.98 |
| Outstanding Share | 1006.23 M |
| Float/ Outstanding Share | 24.74% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 1.97 |
| Peter Lynch Ratio | 0.835 |
| Piotroski F Score | 6.00 |
| Altman Z Score | 6.80 |
| Sloan Ratio | 0.165 |
| Peter Lynch Fair Value | 1041.67 |
ZYDUSLIFE - Growth Highlights
Growth Analysis
Short term positive trend in total sale and net profit
Tremendous increasing trend in total sale last 3 year
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 23607.70 (Cr) | 18.90 % | 0.702 % |
| Gross Profit | 16452.90 (Cr) | 26.91 % | 1.84 % |
| EBITDA | 7139.20 (Cr) | 25.72 % | 16.50 % |
| Net Profit | 4572.40 (Cr) | 17.26 % | 25.27 % |
| EPS | 45.46 | 17.91 % | NA |
ZYDUSLIFE - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 84.38
Altman Z Score of 6.80 suggests good Stability
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ | Screener/ About |
|---|---|---|---|---|
| Debt to Equity Ratio | 0.133 | 238.01 % | 0.121 | |
| Cash Ratio | 0.327 | 58.08 % | ||
| Quick Ratio | 1.45 | -3.95 % | 1.45 | |
| Shareholders Equity | 64.39 | -4.92 % | ||
| Debt to EBITDA | 0.448 | 224.78 % |
Historical Valuation Ratios of Zydus Lifesciences Ltd.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Zydus Lifesciences Ltd.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Zydus Lifesciences Ltd.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Zydus Lifesciences Ltd.
Historical Solvency Ratios
Loading ...